Kuros Biosciences announced results from two prospective, randomized clinical studies - the STRUCTURE and MAXA trials. In the MAXA trial, MagnetOs showed a 73% higher fusion rate relative to autograft in the challenging posterolateral space. In the STRUCTURE trial, Fibrin-PTH, while demonstrating excellent clinical outcomes, showed fusion rates comparable to autograft in the less challenging interbody space.

As a result, Kuros will focus its resources to amplify the continued commercialization of its MagnetOs bone graft family of products. The MAXA trial is an observer-blinded, randomized, intra-patient controlled, multi-center clinical trial which compared MagnetOs standalone to autograft for posterolateral fusion. The STRUCTURE trial is investigating the safety and efficacy of Fibrin-PTH (KUR-113) in single-level transforaminal lumbar interbody fusion (TLIF) procedures, compared to local autograft in the interbody space.

Both treatment groups underwent concomitant posterolateral fusion with MagnetOs mixed with local autograft.